March 28, 2023 7:56am

Tighter fiscal “conditions,” share pricing ranges, uncertain capital markets access, faltering runways are some of the effects of heightened financial market volatility with uncertain sentiment

News: Voyager Therapeutics (VYGR) presented new data from its anti-tau antibody program for Alzheimer’s disease (AD) and from its GBA1 gene therapy program for Parkinson’s disease (PD) and other GBA1-mediated diseases at the AD/PD™ Conference in Gothenburg, Sweden.

Pre-open Indications: 3 Negative Indications and 3 Sell into Strength

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

The 8:00 a.m. edition


Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on will happen behind the headlines today, not tomorrow or yesterday …

 

Dow futures are UP +0.10% or (+30 points), S&P futures are UP +0.02% or (+1 point) and NASDAQ futures are DOWN -0.01% or (-1.25 points) early in the pre-open – so far

Stock futures were split up/down and fluctuating on Tuesday,

European markets were mixed,

Asia-Pacific traded mixed.

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Monday closed with the Dow added 0.6%, while the S&P 500 gained 0.16%. The Nasdaq dipped 0.47%.

Economic Data Docket: next week, the data calendar will be busy, but none of the releases are likely to offer markets direction until Friday …

 

Thursday’s (3/27) … RegMed Investors’ (RMi) closing bell: “a BUY zone or just another algorithm rebound? … https://www.regmedinvestors.com/articles/12890

RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting … “The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth” https://www.regmedinvestors.com/articles/12843 --- 28 of 35 (my coverage group)

 

Ebb and flow:

Q1/23 –

March – 8 positive and 11 negative closes

·         February – 1 holiday, 2 vacation, 7 negative and 8 positive closes

·         January – 2 holidays, 11 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative indications:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

CRISPR Therapeutics (CRSP) closed up +$0.92 after Friday’s +$0.29, Thursday’s -$0.40, Wednesday’s +$1.52, Tuesday’s +$0.60 and last Monday’s -$1.28 with a negative -$0.15 or -0.34% pre-open indication

Ionis Pharmaceuticals (IONS) closed down -$0.23 with a negative -$0.64 or -1.90% aftermarket indication

Sage Therapeutics (SAGE) closed up +$0.47 after Friday’s  +$0.46, Thursday’s +$0.42, Wednesday’s -$1.26, Tuesday’s -$0.69 and last Monday’s +$1.23 with a negative -$0.74 or -1.71% aftermarket indication.

 

Sell into Strength Indications:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Beam Therapeutics (BEAM) closed up +$0.15 with a positive +$0.46 or +1.51% aftermarket indication

Chinook Therapeutics (KDNY) closed up +$0.83 with a positive +0.29 or +1.26% aftermarket indication

Prime Medicine (PRME) closed up +$0.66 after Friday’s -$0.37, Thursday’s -$0.82, Wednesday’s -$0.88, Tuesday’s +$0.38 and last Monday’s +$0.61 with a positive +$0.39 or +3.29% pre-open indication.

 

The BOTTOM LINE: I try to keep it simple and short!

The market and sector are in correction, even though the sector was up on Monday; investors should mostly, if not entirely, be on the sidelines until a follow-through session (Friday was Thursday follow-through) while Monday, I consider a flow-through session.

I do NOT – it might come but, will it last … I believe half-hearty that there is a down side trigger to yet another … SUSTAINABLE uptrend.

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product.

And I can always be WRONG but, I am mostly EARLY!

Also, the rush of Q4 and FY22 earnings to release is slowing …

·         AVRO and SLDB reported last Thursday

·         28 of my 35 covered have reported - 7 remaining

Waiting for announcements …

·         Brainstorm Cell Therapeutics (BCLI) 3/30 - Thursday

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.